SHANGHAI, 27 octobre 2023 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) a annoncé que le premier patient en Europe a reçu une dose, dans le cadre de l’étude clinique internationale multicentrique de phase 3 (NCT05353257) de l’anticorps monoclonal anti-PD-1 HANSIZHUANG…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.